FLGT

Fulgent Genetics' stock has been impacted by several key events in the past six months. The company reported mixed Q3 and Q4 2025 earnings, with a significant stock decline after the Q4 report due to the announced departure of its largest customer. Fulgent Genetics completed the acquisition of Bako Diagnostics and StrataDx on March 17, 2026. Q1 2026 financial results reported a GAAP and non-GAAP loss, but the EPS exceeded analysts' expectations. The company reaffirmed its full-year 2026 revenue guidance, but analyst price targets have been lowered, and the stock has experienced a decrease of 39.2% since the start of 2026.